Gupta to retire at the end of his current term on May 12, 2022, after more than a decade of service, during which time Avantor has transformed into a global life sciences leader
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Funding to grow the insurance and digital therapeutics vertical in India
The funds will be used to expand digital product offerings, grow their online customer base, and launch their flagship clinic in Bengaluru
The entire integration and transition of the brands is expected to be completed by March 2022
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Subscribe To Our Newsletter & Stay Updated
